Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1992 1
2002 1
2003 1
2004 1
2005 1
2006 3
2007 2
2008 1
2009 2
2010 1
2012 4
2013 13
2014 16
2015 19
2016 10
2017 18
2018 20
2019 9
2020 9
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 29580819

118 results
Results by year
Filters applied: . Clear all
Page 1
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A. Tiberi S, et al. Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Lancet Infect Dis. 2018. PMID: 29580819 Review.
Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A. Wallis RS, et al. Lancet Infect Dis. 2016 Apr;16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0. Lancet Infect Dis. 2016. PMID: 27036358 Review.
Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.
Zumla A, Maeurer M; Host-Directed Therapies Network (HDT-NET) Consortium. Zumla A, et al. Clin Infect Dis. 2015 Nov 1;61(9):1432-8. doi: 10.1093/cid/civ631. Epub 2015 Jul 28. Clin Infect Dis. 2015. PMID: 26219693 Free article.
[Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. Zumla AI, et al. Lancet Infect Dis. 2014 Apr;14(4):327-40. doi: 10.1016/S1473-3099(13)70328-1. Lancet Infect Dis. 2014. PMID: 24670627 Review.
Pipeline of drugs for related diseases: tuberculosis.
Dooley KE, Nuermberger EL, Diacon AH. Dooley KE, et al. Curr Opin HIV AIDS. 2013 Nov;8(6):579-85. doi: 10.1097/COH.0000000000000009. Curr Opin HIV AIDS. 2013. PMID: 24100880 Free PMC article. Review.
The challenge of the new tuberculosis drugs.
Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB. Tiberi S, et al. Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Presse Med. 2017. PMID: 28256383 Review. French.
Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future.
Rao M, Ippolito G, Mfinanga S, Ntoumi F, Yeboah-Manu D, Vilaplana C, Zumla A, Maeurer M. Rao M, et al. Int J Infect Dis. 2019 Mar;80S:S62-S67. doi: 10.1016/j.ijid.2019.01.039. Epub 2019 Jan 24. Int J Infect Dis. 2019. PMID: 30685590 Free article.
Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
Palucci I, Delogu G. Palucci I, et al. Chemotherapy. 2018;63(3):172-180. doi: 10.1159/000490478. Epub 2018 Jul 20. Chemotherapy. 2018. PMID: 30032143 Free article. Review.
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
Zumla A, Rao M, Dodoo E, Maeurer M. Zumla A, et al. BMC Med. 2016 Jun 15;14:89. doi: 10.1186/s12916-016-0635-1. BMC Med. 2016. PMID: 27301245 Free PMC article. Review.
118 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page